Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors
- PMID: 11221860
Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors
Abstract
Replicating adenoviruses (Ads) are designed to replicate in and destroy cancer cells, generating viral progeny that spread within the tumor. To address the importance of the primary cellular receptor for Ads, the coxsackievirus and Ad receptor (CAR), in permitting intratumoral spread of a replicating Ad, we have used a pair of tumor cell lines differing only in the expression of a primary receptor for Ad5. This novel system thus allowed the first direct evaluation of the relationship between the efficacy of a replicating Ad and the primary receptor levels of the host cell without the confounding influence of other variable cellular factors. We demonstrate that the absence of the primary cellular receptor on the tumor cells restricts the oncolytic potency of a replicating Ad both in vitro and in vivo. Based on these findings, it is apparent that the potential therapeutic advantages afforded by viral replication would be negated by poor intratumoral spread of the viral progeny due to the failure to infect neighboring tumor cells. Because a number of studies have reported that primary cancer cells express only low levels of CAR, our results suggest that strategies to redirect Ads to achieve CAR-independent infection will be necessary to realize the full potential of replicating Ads in the clinical setting.
Similar articles
-
Substitution of the adenovirus serotype 5 knob with a serotype 3 knob enhances multiple steps in virus replication.Cancer Res. 2003 Mar 15;63(6):1262-9. Cancer Res. 2003. PMID: 12649186
-
Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors.Cancer Res. 2002 Aug 1;62(15):4273-81. Cancer Res. 2002. PMID: 12154029
-
Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma.J Gene Med. 2005 May;7(5):584-94. doi: 10.1002/jgm.703. J Gene Med. 2005. PMID: 15651070
-
Current developments in adenovirus-based cancer gene therapy.Future Oncol. 2006 Feb;2(1):137-43. doi: 10.2217/14796694.2.1.137. Future Oncol. 2006. PMID: 16556080 Free PMC article. Review.
-
Unity and diversity in the human adenoviruses: exploiting alternative entry pathways for gene therapy.Biochem J. 2010 Nov 1;431(3):321-36. doi: 10.1042/BJ20100766. Biochem J. 2010. PMID: 20937040 Review.
Cited by
-
SPECT/CT imaging of hNIS-expression after intravenous delivery of an oncolytic adenovirus and 131I.PLoS One. 2012;7(3):e32871. doi: 10.1371/journal.pone.0032871. Epub 2012 Mar 7. PLoS One. 2012. PMID: 22412937 Free PMC article.
-
NanoBiT System and Hydrofurimazine for Optimized Detection of Viral Infection in Mice-A Novel in Vivo Imaging Platform.Int J Mol Sci. 2020 Aug 15;21(16):5863. doi: 10.3390/ijms21165863. Int J Mol Sci. 2020. PMID: 32824188 Free PMC article.
-
Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer.J Cancer Res Clin Oncol. 2012 Apr;138(4):603-10. doi: 10.1007/s00432-011-1135-5. Epub 2012 Jan 1. J Cancer Res Clin Oncol. 2012. PMID: 22209976
-
Immunohistochemical Characterization and Sensitivity to Human Adenovirus Serotypes 3, 5, and 11p of New Cell Lines Derived from Human Diffuse Grade II to IV Gliomas.Transl Oncol. 2017 Oct;10(5):772-779. doi: 10.1016/j.tranon.2017.07.002. Epub 2017 Aug 4. Transl Oncol. 2017. PMID: 28797937 Free PMC article.
-
Downregulation of Mcl-1 synergizes the apoptotic response to combined treatment with cisplatin and a novel fiber chimeric oncolytic adenovirus.Oncol Rep. 2012 Apr;27(4):971-8. doi: 10.3892/or.2012.1636. Epub 2012 Jan 16. Oncol Rep. 2012. PMID: 22266706 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources